文献速递神经肿瘤

脑膜瘤分级与增殖、缺氧及血管分子标志物对长期预后的预测价值

Meningioma grade and molecular markers of proliferation, hypoxia, and vascularity as predictors of outcome in a cohort with long-term patient follow-up.
PubMed 文献 · J Neurooncol · 2025-10-15

该研究回顾性分析1991至2011年切除的132例患者共143个颅内脑膜瘤,按WHO 2021标准重新分级,中位随访17.1年。结果发现WHO 2021 2级、MIB-1>5%和瘤周水肿比独立预测无进展生存,次全切除和WHO 2021 2级预测总生存,缺氧/血管标志物在多变量模型中无显著性。

要点

  • WHO 2021 2级、MIB-1>5%和瘤周水肿比可分层无进展生存。
  • 次全切除与WHO 2021 2级与总生存受损独立相关。
  • 缺氧与血管标志物在多变量模型中未显示独立预后价值。

核心结论

  • 按WHO 2021重新分级并长期随访,分级、MIB-1和瘤周水肿比可分层无进展生存,切除程度和分级预测总生存。

研究设计与样本

  • 回顾性队列研究,纳入1991至2011年切除的132例患者共143个颅内脑膜瘤,按WHO 2021标准重新分级。

主要发现

  • 中位随访17.1年,无进展生存独立相关因素为WHO 2021 2级(HR 3.72,95%CI 1.49-9.32)、MIB-1>5%(HR 2.56,95%CI 1.17-5.60)和瘤周水肿比(每增加0.1,HR 1.22,95%CI 1.04-1.43)。
  • 总生存相关因素为次全切除(HR 2.69,95%CI 1.28-5.65)和WHO 2021 2级(HR 4.27,95%CI 1.61-11.33)。
  • 缺氧和血管生成标志物在多变量模型中无显著性。
  • 中位无进展生存未达到,3年和5年估计值分别为84.1%和79.6%。

关键数值与推荐

  • 无进展生存多变量模型纳入WHO 2021 2级、MIB-1>5%和瘤周水肿比。
  • 总生存多变量模型纳入次全切除与全切除比较及WHO 2021 2级。
  • 免疫组化标志物包括增殖(MIB-1)、缺氧(GLUT-1、HIF-1α、CA-IX)、血管生成(VEGF)和血管密度(MVD),采用预设阈值。

临床怎么用

  • 在分子分型不可及时,可用WHO 2021分级、MIB-1和瘤周水肿比辅助预后咨询与随访策略。
  • 次全切除与总生存受损相关,提示应关注切除程度对长期生存的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To identify clinical, pathologic, and imaging predictors of progression and survival in intracranial meningioma using the 2021 World Health Organization (WHO) grading system with long-term follow-up. METHODS: We retrospectively analyzed 132 patients (143 tumors) resected from 1991 to 2011 and regraded tumors per WHO 2021 criteria. Outcomes were progression-free survival (PFS) and overall survival (OS). Immunohistochemical markers from archival tissue included proliferation (MIB-1), hypoxia (GLUT-1, HIF-1α, CA-IX), angiogenesis (VEGF), and vascularity (microvascular density [MVD]) with prespecified thresholds. Preoperative tumor and peritumoral brain edema (PTBE) volumes were segmented to calculate a PTBE ratio (edema: tumor). Cox models evaluated covariates (PFS: WHO 2021 grade 2, MIB-1 > 5%, PTBE ratio; OS: subtotal vs. gross total resection, WHO 2021 grade 2). RESULTS: Median follow-up was 17.1 years. PFS was independently associated with WHO 2021 grade 2 (HR 3.72, 95% CI 1.49-9.32), MIB-1 > 5% (HR 2.56, 95% CI 1.17-5.60), and PTBE ratio (HR 1.22 per 0.1 increment, 95% CI 1.04-1.43). OS was associated with subtotal resection (HR 2.69, 95% CI 1.28-5.65) and WHO 2021 grade 2 (HR 4.27, 95% CI 1.61-11.33). Hypoxia/angiogenesis markers were not significant in multivariable models. Median PFS was not reached; 3- and 5-year estimates were 84.1% and 79.6%. CONCLUSIONS: With WHO 2021 regrading and extended follow-up, grade, MIB-1, and PTBE stratify PFS, whereas extent of resection and grade predict OS. These accessible factors may guide counseling and surveillance where molecular profiling is unavailable.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Jhandi S, Goold E, Jensen RL, et al. Meningioma grade and molecular markers of proliferation, hypoxia, and vascularity as predictors of outcome in a cohort with long-term patient follow-up. J Neurooncol. 2025. PMID: 41094320. doi:10.1007/s11060-025-05236-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。